Fixed-dose combinations of inhaled corticosteroids (ICSs) and long-acting β2-agonists
(LABAs) have been used to manage asthma for several years. They are the preferred …

Background Combination therapy with inhaled corticosteroids (ICSs) and long-acting β 2-
agonists (LABAs), or treatment with high doses of ICSs alone improves asthma control when …

Asthma treatment guidelines advocate the use of long-acting β2-agonists (LABA) in addition
to inhaled corticosteroids (ICS) in patients whose asthma is uncontrolled by ICS alone …

Inhaled corticosteroids (ICS) are the mainstay of asthma treatment. Since 1994, when the
first trial showed an equivalent effect of doubling the ICS dose or adding salmeterol, it has …

In the recent years, considerable insight has been gained in to the optimal management of
adult asthma. Most adult patients with asthma have mild intermittent and persistent disease …

Combination therapy with inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA)
is a recognized treatment for adults with moderate to severe asthma. The introduction of …

The addition of long-acting beta-agonists to inhaled cortico... : Current Opinion in Pulmonary
Medicine The addition of long-acting beta-agonists to inhaled corticosteroids in asthma …

BACKGROUND: Guidelines recommend that for patients uncontrolled on inhaled
corticosteroids (ICSs), step-up options include an increase in ICS dosage or addition of a …

Long‐acting inhaled β2‐Agonists and inhaled corticosteroids are classes of drugs with
different mechanisms of action that are commonly used to provide effective long‐term control …

Inhaled corticosteroids (ICSs) have been recommended as a maintenance treatment, either
alone or together with long-acting inhaled β2-agonists, for all asthma patients. Short-acting …